Page last updated: 2024-08-05 12:25:33
naphthofuran
null
ChEBI ID: 39270
Members (15)
| Member | Definition | Role |
|---|
| 2-(1-benzo[e]benzofuranyl)-N-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]acetamide | | 2-(1-benzo[e]benzofuranyl)-N-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]acetamide |
| 3-acetyl-2-methylbenzo[f]benzofuran-4,9-dione | | 3-acetyl-2-methylbenzo[f]benzofuran-4,9-dione |
| 3-methyl-2-benzo[g]benzofurancarboxylic acid [2-[N-(2-cyanoethyl)anilino]-2-oxoethyl] ester | | 3-methyl-2-benzo[g]benzofurancarboxylic acid [2-[N-(2-cyanoethyl)anilino]-2-oxoethyl] ester |
| 5-hydroxy-2-methyl-3-benzo[g]benzofurancarboxylic acid ethyl ester | | 5-hydroxy-2-methyl-3-benzo[g]benzofurancarboxylic acid ethyl ester |
| 5-hydroxy-2-methyl-4-[1-piperidinyl(3-pyridinyl)methyl]-3-benzo[g]benzofurancarboxylic acid ethyl ester | | 5-hydroxy-2-methyl-4-[1-piperidinyl(3-pyridinyl)methyl]-3-benzo[g]benzofurancarboxylic acid ethyl ester |
| alantolactone | A sesquiterpene lactone that is 3a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2-one bearing two methyl substituents at positions 5 and 8a as well as a methylidene substituent at position 3. | alantolactone |
| ambrox | | Ambronide |
| atractylenolide iii | | Atractylenolide III |
| diosbulbin b | | Diosbulbin B |
| dunnione | | Dunnione |
| N-(9,9-dimethyl-7-oxo-8,10-dihydronaphtho[1,2-b]benzofuran-5-yl)-4-methoxybenzenesulfonamide | | N-(9,9-dimethyl-7-oxo-8,10-dihydronaphtho[1,2-b]benzofuran-5-yl)-4-methoxybenzenesulfonamide |
| N-[(4-methoxyphenyl)methyl]-2-methyl-4,9-dioxo-3-benzo[f]benzofurancarboxamide | | N-[(4-methoxyphenyl)methyl]-2-methyl-4,9-dioxo-3-benzo[f]benzofurancarboxamide |
| N-cyclopentyl-2-benzo[e]benzofurancarboxamide | | N-cyclopentyl-2-benzo[e]benzofurancarboxamide |
| sclareolide | | Norambreinolide |
| vorapaxar | A carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethynyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation. | vorapaxar |
Research
Studies (494)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|
| pre-1990 | 11 (2.23) | 18.7374 |
| 1990's | 10 (2.02) | 18.2507 |
| 2000's | 48 (9.72) | 29.6817 |
| 2010's | 332 (67.21) | 24.3611 |
| 2020's | 93 (18.83) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|
| Trials | 57 (10.23%) | 5.53% |
| Reviews | 84 (15.08%) | 6.00% |
| Case Studies | 4 (0.72%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 412 (73.97%) | 84.16% |